Formulary conversion programs: the need for patient-specific risk assessment.
Singh
Sonal
S
Department of Internal Medicine, Unity Health System, Rochester, New York, USA.
Shrivastava
Rakesh
R
Das
Vijay
V
D000368:Aged; D000069059:Atorvastatin; D016572:Cyclosporine / Q000009:adverse effects; D004347:Drug Interactions; D005260:Female; D005569:Formularies as Topic; D016027:Heart Transplantation; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000009:adverse effects; D011182:Postoperative Care; D011758:Pyrroles / Q000627:therapeutic use*; D012206:Rhabdomyolysis / Q000139:chemically induced*; D018570:Risk Assessment; D019821:Simvastatin / Q000009:adverse effects*
D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007166:Immunosuppressive Agents; D011758:Pyrroles; D016572:Cyclosporine; D000069059:Atorvastatin; D019821:Simvastatin